Daavlin

Sources

Weischer M, Blum A, Eberhard F, Rocken M, Berneburg M. No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study. Acta Derm Venereol. 2004;84:370-374. doi: 10.1080/00015550410026948.

 

Kircik L, Bagel J, Korman N, et al. Utilization of narrow-band ultraviolet light B therapy and Etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. Journal of Drugs in Dermatology. 2008;7(3):245-253.

 

Kaykal KA, DesGroseilliers JP. Are narrow-band ultraviolet B home units a viable option for continuous or maintenance therapy of photoresponsive diseases?. Journal of Cutaneous Medicine and Surgery. 2006;10(5):234-240.

 

Vano-Galvan S, GarateMT, Fleta-Asin B, et al. Analysis of the cost effectiveness of home-based phototherapy with narrow-band UV-B radiation compared with biological drugs for the treatment of moderate to severe psoriasis. Actas Dermo-Sifiliograficas. 2012;103:127-137.

 

Koek MBG, Buskens E, Weelden H, Steegmans PHA, Bruijnzeel-Koomen CAFM, Sigurdsson V. Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomized controlled non-inferiority trial (PLUTO study). BMJ. 2009;338:b1542. doi:10:1136/bmj.b1542.

 

Yentzer BA, Yelverton CB, Pearce DJ, et al. Adherence to acitretin and home narrowband ultraviolet B phototherapy in patients with psoriasis. Journal of the American Academy of Dermatology. 2008:59(4):577-581. doi:10.1016/j.jaad.2008.06.007.

 

Hearn RMR, Kerr AC, Rahim KF, FergusonJ, Dawe RS. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. British Journal of Dermatology. 2008;159:931-935. doi: 10.1111/j.1365-2133.2008.08776.x.